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Abstract
Background A larger defect in the annulus fibrosus following lumbar discectomy is a well-known risk factor for reherniation.
Procedures intended to prevent reherniation by sealing or occluding the annular defect warrant study in high-risk patients. This
study sought to determine 3-year results of lumbar discectomy with a bone-anchored annular closure device (ACD) or lumbar
discectomy only (controls) in patients at high risk for reherniation.
Methods This multicenter randomized trial enrolled patients with sciatica due to lumbar intervertebral disc herniation who failed
conservative treatment. Patients with large annular defects after lumbar limited microdiscectomy were intraoperatively randomly
assigned to receive ACD or control. Clinical and imaging follow-up was performed at routine intervals over 3 years. Main
outcomes included rate of reherniations, reoperations, and endplate changes; leg and back pain scores on a visual analogue scale;
Oswestry Disability Index (ODI); Physical Component Summary (PCS) and Mental Component Summary (MCS) scores from
the SF-36; and adverse events adjudicated by a data safety monitoring board.
Results Among 554 randomized patients, the modified intent-to-treat population consisted of 272 patients in which ACD
implantation was attempted and 278 receiving control; device implantation was not attempted in 4 patients assigned to ACD.
Outcomes at 3 years favored ACD for symptomatic reherniation (14.8% vs. 29.5%; P < 0.001), reoperation (11.0% vs. 19.3%;
P = 0.007), leg pain (21 vs. 30; P < 0.01), back pain (23 vs. 30; P = 0.01), ODI (18 vs. 23; P = 0.02), PCS (47 vs. 44; P < 0.01),
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and MCS (52 vs. 49; P < 0.01). The frequency of all-cause serious adverse events was comparable between groups (42.3% vs.
44.5%; P = 0.61).
Conclusions The addition of a bone-anchored ACD in patients with large annular defects following lumbar discectomy reduces
the risk of reherniation and reoperation, and has a similar safety profile over 3-year follow-up compared with lumbar limited
discectomy only.
Trial registration ClinicalTrials.gov NCT01283438
Keywords Annular closure device . Annulus fibrosus . Disc herniation . Lumbar discectomy . Randomized controlled trial .
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Introduction
Lumbar discectomy is an effective surgery for chronic sciatica
secondary to intervertebral disc herniation. However, symp-
tom recurrence following surgery is a common risk that is
influenced by patient- and surgery-related factors such as male
sex, disc degeneration, and large post-surgical annular defect
size [8]. Patients with a post-surgical annular defect of at least
6 mm in width have a reherniation risk nearly three times
higher compared with patients with smaller defects [13].
Consequently, adjunctive treatments intended to contain the
nucleus pulposus within the disc space following discectomy
have been studied. So far, results have been disappointing
with sutures, fibrin glue, and polyethylene plug due to the
failure of these materials to chronically withstand high
intradiscal pressures [1, 2, 5, 7]. An implantable device
intended to provide a more durable repair has been developed.
This annular closure device (ACD) anchors into the adjacent
vertebral body and occludes the damaged annulus fibrosus
with a polymer mesh. Results from case series [4, 11, 12,
15] and a recent randomized trial [17] with this device have
demonstrated clinically important reductions in reherniation
and reoperation rates through 2 years. In this report, we extend
these findings by presenting 3-year results from a randomized
trial of 554 patients who received lumbar discectomy with
bone-anchored annular closure or lumbar microdiscectomy
only.
Materials and methods
This was a multicenter, multinational, randomized controlled
trial to determine the effectiveness and safety of lumbar
discectomywith a bone-anchored implant designed to provide
annulus fibrosus occlusion in patients at high risk for
reherniation (ClinicalTrials.gov NCT01283438). Local ethics
committees reviewed and approved the protocol. All partici-
pants provided written informed consent before trial partici-
pation. The design [9] and 2-year primary endpoint results
[17] of this trial have previously been described. This report
presents 3-year clinical and radiographic results from the trial.
Preoperative imaging included magnetic resonance imag-
ing (MRI) with T1- and T2-weighted axial and sagittal im-
ages, index-level low-dose multiplanar computed tomography
(CT), and anteroposterior/lateral and flexion/extension x-rays.
Important eligibility criteria for the study included diagnosis
of a single-level lumbar disc herniation identified on preoper-
ative imaging, and concurrent clinical findings (positive
straight leg raise or femoral stretch test) with leg pain (≥ 40
on a 0–100 visual analogue scale) that were not responsive to
at least 6 weeks of conservative treatment, and at least mod-
erate disability (≥ 40 on the Oswestry Disability Index). A
complete list of study entry criteria is provided in
Supplement Table 1. Patients meeting these criteria were treat-
ed with limited lumbar microdiscectomy but were not yet
enrolled in the study. When the discectomy procedure was
completed, the final study entry criterion was applied.
Patients with a large defect in the annulus fibrosus, defined
as 4–6-mm height and 6–10-mm width, were enrolled in the
study and randomly allocated (1:1) to receive discectomy only
(controls) or to additionally receive a bone-anchored ACD
with a mesh occlusion component (Barricaid, Intrinsic
Therapeutics, Woburn, MA, USA) designed to physically
block the annular defect. Patients with large annular defects
were specifically targeted for this trial given their well-known
high risk of reherniation after lumbar discectomy [13].
Following randomization, no additional disc material was re-
moved in either treatment group. When annular defects of
ineligible size were intraoperatively identified, the discectomy
procedure was completed in the usual fashion and patients
were discontinued from the study.
Clinical and imaging follow-up occurred at 6 weeks,
3 months, 6 months, and at annual intervals for 3 years and
included MRI, low-dose CT, and AP/lateral and flexion/
extension x-rays. Patients in this study will remain in follow-
up for 5 years. A schematic that lists the clinical and imaging
tests performed at each study interval is provided in
Supplement Table 2. Symptomatic reherniation was defined
as a reherniation (protrusion, extrusion, or sequestration) that
was confirmed during a reoperation, or identified on imaging
with associated recurrent or new lumbar pain, leg pain, or
neurological deficit. Reoperation included any repeat proce-
dure at the index level of herniation including discectomy,
1390 Acta Neurochir (2019) 161:1389–1396
supplemental fixation, fusion, or device explant. Key radio-
graphic assessment by x-ray and CT included disc height,
device status, and vertebral endplate changes (VEPC).
Imaging evaluations were read by an independent core labo-
ratory radiologist who was blinded to clinical outcomes.
Clinical outcome parameters included leg and back pain se-
verity, Oswestry Disability Index (ODI), SF-36 Physical
Component Summary (PCS) score, and SF-36 Mental
Component Summary (MCS) score. The minimal important
differences (MID) were defined as a ≥ 20-point decrease from
baseline for leg pain [14], ≥ 20-point decrease from baseline
for back pain [14], ≥ 15-point decrease from baseline for ODI
[6], ≥ 5.7-point increase from baseline for PCS [18], and ≥
6.3-point increase from baseline for MCS [18]. Neurological
status and adverse events were assessed at each follow-up
visit. Investigators classified adverse events by seriousness
and relation to the device or procedure. Neither patients, sur-
geons, outcome assessors nor imaging core laboratory readers
were blinded to group allocation, with the exception of pa-
tients in the Netherlands due to regional regulations. An inde-
pendent data safety monitoring board provided safety over-
sight during the study and adjudicated all adverse events.
Statistical analyses were performed on a modified
intention-to-treat population consisting of randomized pa-
tients in whom the intended procedure was attempted.
Preoperative group characteristics were reported as mean
and standard deviation for continuous variables, and count
and percentage for categorical variables. Group comparisons
were performed with Student’s t test for continuous data,
Fisher’s exact test for categorical data, and log-rank tests for
survival data. In patients who underwent a reoperation prior to
the 3-year follow visit, leg pain, back pain, ODI, PCS, and
MCS values at 3 years were substituted with baseline values.
Statistical significance was set at P < 0.05 and hypothesis test-
ing was two-sided. Statistical analyses were performed using
SAS v9.4 (SAS Institute, Cary, NC, USA) and R v3.3.2 (R
Foundation for Statistical Computing, Vienna, Austria).
Results
A total of 554 patients were randomly allocated to receive
ACD (n = 276) or control (n = 278) at 21 hospitals (Study
Group Appendix Table 4)) between December 2010 and
October 2014. Annular closure device implantation was not
attempted in four patients because of the close proximity of
the nerve root and the associated potential risk. Therefore, the
modified intention-to-treat population included 272 ACD pa-
tients and 278 control patients. Among the ACD group were 5
patients in which the device was unsuccessfully implanted due
to incomplete entry of the occlusion mesh into the disc space
(n = 4) or nerve root injury (n = 1). The mean age of all en-
rolled patients was 43 ± 11 years and 59% were men. Disc
herniation was most commonly identified at L5-S1 (56%) or
L4-L5 (41%). Patients typically presented with severe leg pain
(overall mean 81 ± 15), severe disability (overall mean ODI
59 ± 13), and moderate back pain (overall mean 56 ± 31)
(Table 1). Overall, 415 (75%) patients (207ACD, 208 control)
returned for clinical follow-up at 3 years (Fig. 1).
The risk of symptom recurrence through 3 years was lower
in patients treated with ACD versus controls; the cumulative
incidence of symptomatic reherniation was 8.4% vs. 17.4% at
1 year, 10.7% vs. 23.4% at 2 years, and 14.8% vs. 29.5% at
3 years (log-rank P < 0.001 at 3 years) (Fig. 2). Similarly,
reoperations were less frequent in the ACD group, with cu-
mulative reoperation rates of 6.7% vs. 12.9% at 1 year, 9.0%
vs. 16.4% at 2 years, and 11.0% vs. 19.3% at 3 years (log-rank
P < 0.001 at 3 years) (Fig. 3). There were 38 reoperations in
29 ACD patients and 70 reoperations in 51 control patients.
Reoperation strategies between groups were similar with re-
peat discectomy performed most frequently (Table 2).
Patient-reported outcomes favored those treated with the
ACD. Comparing ACD with controls, mean values at 3 years
were 21 vs. 30 (mean difference = − 8, 95% CI = − 2 to − 15,
P < 0.01) for leg pain, 23 vs. 30 (mean difference = − 7, 95%
CI = − 1 to − 12, P = 0.01) for back pain, and 18 vs. 23 (mean
difference = − 5, 95% CI = − 1 to − 9, P = 0.02) for ODI.
Health-related quality of life scores at 3 years was higher in
the ACD group; PCS scores were 47 vs. 44 (mean difference
= 3, 95%CI = 1 to 5,P < 0.01) andMCS scores were 52 vs. 49
(mean difference = 3, 95% CI = 1 to 5, P < 0.01). The percent-
age of patients achieving the MID was statistically greater in
the ACD group for leg pain, ODI, PCS, and MCS; no
Table 1 Baseline patient characteristics
Characteristic ACD (n = 272) Control (n = 278)
Age (year) 43 ± 11 44 ± 10
Male sex 156 (57) 171 (62)
Body mass index (kg/m2) 26 ± 4 26 ± 4
Smoking history 173 (64) 175 (63)
Leg pain severity (mm) 81 ± 15 81 ± 15
Back pain severity (mm) 57 ± 30 56 ± 31
Oswestry Disability Index 59 ± 12 58 ± 14
Index level
L2-L3 2 (1) 1 (< 1)
L3-L4 8 (3) 5 (2)
L4-L5 123 (45) 101 (36)
L5-S1 139 (51) 171 (62)
Spondylolisthesis, grade 1 6 (2) 8 (3)
Disc height (mm) 8.9 ± 2.1 8.9 ± 2.2
Extrusion or sequestration 201 (74) 201 (72)
Values are mean±standard deviation or count (percentage)
ACD, annular closure device
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statistical difference between groups was noted for back pain
(P = 0.08) (Fig. 4).
Disc height decreased by approximately 30% in each group
relative to baseline. Average disc height at 3 years was 6.3 ±
2.2 mm with ACD and 6.4 ± 2.2 mm with controls (P = 0.64).
Vertebral endplate changes were identified by the imaging
core laboratory in 89% of ACD patients and in 41% of con-
trols (P < 0.001). The median VEPC areas at 2- and 3-year
Fig. 1 Enrollment and
randomization of patients.
Among 554 randomized patients,
276 were allocated to annular
closure device (ACD) and 278 to
control. Owing to 4 patients in
whom ACD implant was not
attempted, the modified intent-to-
treat population consisted of 272
patients with attempted ACD
implant and 278 patients assigned
to control. Compliance with
clinical follow-up at 3 years was
76% with ACD and 75% with
controls
Fig. 2 Cumulative rate of symptomatic index level reherniation through
3 years. Cumulative event rates were 14.8% for annular closure device
(ACD) and 29.5% for control (log-rank P < 0.001)
Fig. 3 Cumulative rate of index level reoperation through 3 years.
Cumulative event rates were 11.0% for annular closure device (ACD)
and 19.3% for control (log-rank P < 0.001)
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follow-up were 0.42 cm3 and 0.49 cm3 with ACD, 0.29 cm2
and 0.42 cm2 for controls. Neither the frequency, area, nor
growth trajectory of VEPC was associated with clinical
sequelae.
Neurological function deterioration relative to baseline
was reported in 2.0% of ACD patients and 4.3% of con-
trols at 3 years (P = 0.26). Serious adverse events related
to the device or procedure occurred in 10.7% of the
ACD group and in 18.7% of controls (P = 0.008), and
were mainly attributable to lumbar disc reherniation
(Table 3). Serious adverse events due to device deficien-
cy were reported in 12 (4.4%) patients in the ACD group
and included mesh migration (n = 5), mesh detachment
(n = 3), anchor migration (n = 3), and anchor fracture
(n = 1). Reherniation was identified at the time of reop-
eration in four of these patients. The frequency of all
serious adverse events (Supplement Table 3) and all ad-
verse events regardless of seriousness (Supplement
Table 4) was comparable between groups.
Discussion
A large unrepaired defect in the annulus fibrosus at comple-
tion of a lumbar discectomy procedure places patients at high
risk for reherniation [13], which requires a reoperation in most
cases to adequately resolve radicular symptoms [16]. In this
randomized trial of high-risk patients, implantation with a
bone-anchored ACD following limited lumbar discectomy re-
duced the risk of reherniation and reoperation and therefore
achieved a better long-term pain and disability relief with as-
sociated higher levels of health-related quality of life com-
pared with lumbar discectomy only. There were some specific
risks to the ACD only, which included implantation difficul-
ties, radiographic device deficiencies such as migration, mesh
detachment, and VEPC. However, the overall safety profile
was generally comparable between groups. These results sug-
gest that lumbar discectomy with additional ACD implanta-
tion is an effective and safe procedure over 3-year follow-up
in well-selected patients at high risk for reherniation owing to
a large post-surgical annular defect.
Perhaps the most important finding of this trial relates to
the ability of the ACD to lower the risk of recurrent herniation
and reoperation among high-risk patients. This finding is no-
table given the previous failures of alternative annular defect
closure methods such as sutures or fibrin glue [1, 2, 5, 7]. The
fact that the mesh occlusion component is attached to an an-
chor within the vertebral body is the likely differentiating
characteristic that offers a more durable annular occlusion.
Several different mechanisms of device failure occurred, in-
cluding mesh detachment, device migration, and anchor frac-
ture. Most device failures were observed on follow-up imag-
ing with no associated patient symptoms. However, device
failure was associated with clinical sequelae in 4% of patients.
All anchor migrations were observed within 3 months of sur-
gery; two in patients with low regional bone density and one
in a patient with multiple risk factors (heavy smoking, obesity,
diabetes). It appears that device deficiencies, biomechanical
forces, and/or patient characteristics may be causative factors
involved in observed ACD failures.
Vertebral endplate changes detected on CT were more com-
mon among patients treated with ACD versus controls. While a
detailed accounting of the association of VEPC with clinical
outcomes is beyond the scope of this paper, the key findings
warrant discussion. A noncontrolled study of 85 patients under-
going lumbar discectomy with or without additional ACD re-
ported similar results where VEPC prevalence was higher in
patients treated with ACD (52% vs. 10%), yet the reherniation
rate on imaging irrespective of symptoms was lower with ACD
(5% vs. 50%) [3]. Our group previously reported 2-year data
from the current trial [10], which arrived at similar conclusions
as with the current 3-year data. The presence of VEPC was not
associated with patient-reported outcomes (leg pain, back pain,
ODI) at 3 years after lumbar discectomy. Further, VEPC growth
Fig. 4 Percentage of patients achieving the minimal clinically important
difference (MID) in patient-reported outcomes through 3 years. MID
defined as improvement from baseline of at least 20 points for leg pain,
20 points for back pain, 15 points for Oswestry Disability Index (ODI),
5.7 points for Physical Component Score (PCS), and 6.3 points for
Mental Component Score (MCS), respectively (all reported on 0–100
scale). Statistical significance between treatment groups denoted as
*P < 0.05 or †P < 0.01. ACD, annular closure device




ACD removal only 5 NA
Decompression procedure 3 2
Wound complication 1 6
Dural tear repair 1 0
Discectomy with ACD implant NA 4
Hematoma drainage 0 3
Total 38 70
ACD, annular closure device; NA, not applicable
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appears to be self-limiting with larger defects growing at the
slowest rates. Based on the 3-year results of this trial, VEPCs
occur more commonly with ACD, stabilize over time, and are
not associated with adverse clinical sequelae.
Patient-reported outcomes statistically favored the ACD
group at 3 years. However, the clinical implications of these
findings are unclear since the mean differences between
groups ranged from 0.3 to 0.6 MID units, depending on the
outcome. A likely explanation for these modest differences is
that this was a trial of a device intended to prevent, not treat,
herniation recurrence. Since lumbar discectomy results in a
durable surgical repair in 70–80% of cases, the benefit of an
ACD would be realized only in the subsample of patients in
which a reherniation was prevented but would not be antici-
pated to impact patient-reported outcomes otherwise. Based
on the incidence of events and the risk reduction achieved
with ACD, the number of patients needed to treat with ACD
to prevent one symptomatic reherniation is 7; the number
needed to treat to prevent one reoperation is 12.
Important strengths of this study were the multicenter ran-
domized design, large sample size sufficient to detect even rare
adverse events, and comprehensive independent review of im-
aging and adverse events during the trial. There are also several
limitations of this study. First, these results are not applicable to
all patients undergoing lumbar discectomy, but only the approx-
imately 30% of cases at high risk of reherniation due to a large
post-surgical annular defect [13]. The ACD is not intended to be
used in patients with smaller defects since treatment with a per-
manent implant is difficult to justify in this population due to the
relatively low risk of reherniation. Second, lack of patient and
outcome-assessor blinding to treatment allocation may have bi-
ased patient-reported outcomes or the decision to reoperate.
Table 3 Device- or procedure-
related serious adverse events
through 3 years
Event ACD (n = 272) Control (n = 278) P value
Events Patients % Events Patients %
Any device or procedure-related
SAE
39 29 10.7% 69 52 18.7% 0.008
Cardiac and vascular 0 0 0.0% 2 2 0.7% 0.499
Cardiac and vascular - other 0 0 0.0% 2 2 0.7%
Device deficiency 11 11 4.0% NA NA
Anchor (whole device) migration 2 2 0.7%
Mesh migration - extradiscal 4 4 1.5%
Mesh migration - intradiscal 1 1 0.4%
Mesh detachment - extradiscal 2 2 0.7%
Mesh detachment - intradiscal 1 1 0.4%
Anchor fracture 1 1 0.4%
Disc herniation 20 17 6.3% 54 45 16.2% < 0.001
Index level 18 15 5.5% 54 45 16.2%
Residual herniation - index level 2 2 0.7% 0 0 0.0%
Musculoskeletal - lumbar 0 0 0.0% 1 1 0.4% 1.000
Other 0 0 0.0% 1 1 0.4%
Neurological - lumbar and lower
extremity
1 1 0.4% 0 0 0.0% 0.495
Nerve or spinal root injury: index
surgery
1 1 0.4% 0 0 0.0%
Pain - lumbar and lower extremity 4 4 1.5% 4 2 0.7% 0.446
Lower extremity only 2 2 0.7% 3 2 0.7%
Lumbar 1 1 0.4% 0 0 0.0%
Lumbar and lower extremity 1 1 0.4% 1 1 0.4%
Wound complication at index level 3 3 1.1% 8 6 2.2% 0.504
Dural injury/tear or CSF leak 1 1 0.4% 1 1 0.4%
Infection 1 1 0.4% 3 2 0.7%
Hematoma 0 0 0.0% 1 1 0.4%
Delayed wound healing 1 1 0.4% 0 0 0.0%
Dehiscence 0 0 0.0% 1 1 0.4%
Deep 0 0 0.0% 2 2 0.7%
ACD, annular closure device; CSF, cerebrospinal fluid leak; NA, not applicable; SAE, serious adverse event
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Third, while CT imaging with core laboratory reading is a
strength of this trial, it may also be perceived as a limitation
since the application of CT findings to routine clinical practice
is unclear. Finally, longer follow-up is needed in this younger
patient population to determine the durability of effect with
ACD and to ensure there are no concerning late-onset safety-
or device-related complications. While there was no association
of VEPC with clinical complications over 3 years among pa-
tients who received ACD, this should be confirmed in long-term
follow-up.
Conclusion
The addition of a bone-anchored ACD to lumbar
discectomy in patients with large post-surgical annular
defects reduces the risk of reherniation and reoperation,
with a better long-term pain and disability relief over 3-
year follow-up compared with lumbar discectomy only.
While the ACD was associated with distinct risks such
as implantation difficulties, device migration, mesh
detachment, and VEPC, the overall risk of complica-
tions was comparable between groups.
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Table 4 (continued)
Site name No. of patients
enrolled
Principal investigator Sub-investigator(s)
Haaglanden Medical Center: Westeinde (Den Haag,
The Netherlands)
1 Jasper Wolfs




Centre Hospitalier Régional Universitaire de Lille (CHRU), Hôpital
Roger Salengro (Lille, France)
2 Richard Assaker
Orthopädische Klinik und Poliklinik Universitätsmedizin Rostock
(Rostock, Germany)
5 Susanne Fröhlich Dorit Panser-Schulz
*PI moved to AZKlina, Brasschaat, Belgium. EC approval at this site to follow patients enrolled at original site. PI at ZNAMiddleheim nowGuidoDua;
‡ PI Mehdorn retired. Former Co-Investigator Jadik now PI
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